Jason Wittes
Stock Analyst at Roth Capital
(2.69)
# 1,888
Out of 5,149 analysts
60
Total ratings
50%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $8.87 | +350.96% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $384.59 | +18.57% | 11 | May 2, 2025 | |
| ALUR Allurion Technologies | Reiterates: Buy | $16 | $0.68 | +2,238.84% | 2 | Mar 21, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $3.06 | +422.88% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $13.03 | +68.84% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $104.29 | -30.96% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.94 | +122.67% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $91.70 | +25.41% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $7.81 | +40.85% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.01 | +890.10% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $100 | $107.85 | -7.28% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.14 | +133.64% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.53 | +1,610.05% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $25.29 | +196.56% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $13.02 | +68.97% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $97.97 | +22.49% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $175.36 | +17.47% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $210.60 | -31.15% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $23.18 | -35.29% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $13.30 | +1,403.76% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $28.88 | -9.97% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $8.87
Upside: +350.96%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $384.59
Upside: +18.57%
Allurion Technologies
Mar 21, 2025
Reiterates: Buy
Price Target: $16
Current: $0.68
Upside: +2,238.84%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $3.06
Upside: +422.88%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $13.03
Upside: +68.84%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $104.29
Upside: -30.96%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.94
Upside: +122.67%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $91.70
Upside: +25.41%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $7.81
Upside: +40.85%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.01
Upside: +890.10%
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $107.85
Upside: -7.28%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $2.14
Upside: +133.64%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.53
Upside: +1,610.05%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $25.29
Upside: +196.56%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $13.02
Upside: +68.97%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $97.97
Upside: +22.49%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $175.36
Upside: +17.47%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $210.60
Upside: -31.15%
Mar 3, 2022
Initiates: Buy
Price Target: $15
Current: $23.18
Upside: -35.29%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $13.30
Upside: +1,403.76%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $28.88
Upside: -9.97%